Currently out of the existing stock ratings of Naureen Quibria, 11 are a BUY (91.67%), 1 are a HOLD (8.33%).

Naureen Quibria

Work Performance Price Targets & Ratings Chart

Analyst Naureen Quibria, currently employed at CAPITAL ONE,

Naureen Quibria’s has documented 22 price targets and ratings displayed on 6 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ONCT, Oncternal Therapeutics at 04-Apr-2023.

Wall Street Analyst Naureen Quibria

Analyst best performing recommendations are on ONCR (ONCORUS ).
CRDF Cardiff Oncology AYLA Ayala Pharmaceuticals  ONCR Oncorus  CMRX Chimerix KZIA Kazia Therapeutics Ltd ADR ONCT Oncternal Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$13

$10.42 (403.88%)

$14

13 days ago
(08-Nov-2024)

0/4 (0%)

$9.76 (301.23%)

Buy

$7

$4.42 (171.32%)

8 months 20 days ago
(01-Mar-2024)

0/4 (0%)

$4.09 (140.55%)

Buy

$5

$2.42 (93.80%)

$6

2 years 1 months 25 days ago
(27-Sep-2022)

1/3 (33.33%)

$3.45 (222.58%)

533

Buy

$25

$23.61 (1698.56%)

3 years 2 months 12 days ago
(09-Sep-2021)

0/1 (0%)

$18.01 (257.65%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Naureen Quibria?

On 2021

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?